Skip to content
Nonprofiteer
← FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS

Form 990 for tax year 2022

Filed by FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS.

Totals

Total revenue
$52,477,819
Total expenses
$8,933,021
Contributions and grants received
$4,948,249
Grants paid
$6,744,524
Program service revenue
$355,507
Investment income
$47,780,150
Other revenue
-$606,087
Total assets, end of year
$63,075,354
Total liabilities, end of year
$7,259,713
Net assets or fund balances, end of year
$55,815,641
Program services expenses (Part IX)
$7,997,230
Management and general expenses
$579,793
Fundraising expenses
$355,998
Program service expenses (Part III)
$7,997,230

Program services were 89.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1c · Fundraising events

    $2,787,000

  • 1f · All other contributions, gifts and grants

    $2,161,249

  • 1g · Noncash contributions included above

    $100,755

  • 2a · Program service revenue: LICENSING REVENUE

    total $355,507 · related or exempt $355,507

  • 3 · Investment income

    total $508,992 · excluded $508,992

  • 7a · Gross sales of assets other than inventory

    securities $15,518,426 · other assets $52,460,463

  • 7b · Less cost or other basis and sales expenses

    securities $14,495,550 · other assets $6,212,181

  • 7c · Gain or loss

    securities $1,022,876 · other assets $46,248,282

  • 7d · Net gain or loss

    total $47,271,158 · excluded $47,271,158

  • 8a · Fundraising events: gross income

    $361,783

  • 8a · Fundraising events: contributions included on line 1c

    $2,787,000

  • 8b · Fundraising events: direct expenses

    $967,870

  • 8c · Net income from fundraising events

    total -$606,087 · excluded -$606,087

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $6,744,524 · program services $6,744,524

  • 5 · Compensation of officers, directors and key employees

    total $485,109 · program services $291,906 · management and general $193,203

  • 7 · Other salaries and wages

    total $408,158 · program services $188,130 · management and general $105,429 · fundraising $114,599

  • 10 · Payroll taxes

    total $36,373 · program services $17,886 · management and general $11,990 · fundraising $6,497

  • 11b · Fees: legal

    total $258,494 · program services $218,635 · management and general $39,859

  • 11c · Fees: accounting

    total $24,665 · management and general $24,665

  • 11f · Fees: investment management

    total $38,460 · management and general $38,460

  • 11g · Fees: other

    total $31 · management and general $31

  • 12 · Advertising and promotion

    total $328,839 · program services $290,455 · fundraising $38,384

  • 13 · Office expenses

    total $11,879 · program services $7,930 · management and general $3,949

  • 17 · Travel

    total $119,811 · management and general $71,954 · fundraising $47,857

  • 22 · Depreciation, depletion and amortization

    total $14,584 · program services $14,584

  • 23 · Insurance

    total $2,844 · management and general $2,844

  • 24a · Other expenses: EDUCATION AND AWARENESS

    total $131,520 · program services $131,520

  • 24b · Other expenses: VIDEO AND PRODUCTION

    total $97,988 · program services $53,700 · management and general $0 · fundraising $44,288

  • 24c · Other expenses: COMPUTER AND SOFTWARE E

    total $75,598 · management and general $65,523 · fundraising $10,075

  • 24d · Other expenses: OTHER FUNDRAISING EXPEN

    total $71,339 · fundraising $71,339

  • 24e · All other expenses

    total $82,805 · program services $37,960 · management and general $21,886 · fundraising $22,959

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $1,369,488 · end of year $54,308,955

  • 2 · Savings and temporary cash investments

    beginning of year $7,165,247 · end of year $4,283,216

  • 3 · Pledges and grants receivable

    beginning of year $1,665,000 · end of year $2,316,785

  • 4 · Accounts receivable

    beginning of year $0 · end of year $237,629

  • 10a · Land, buildings and equipment: cost or other basis

    $43,753

  • 10b · Land, buildings and equipment: accumulated depreciation

    $29,169

  • 10c · Land, buildings and equipment, net

    beginning of year $29,169 · end of year $14,584

  • 12 · Investments: other securities

    beginning of year $6,380,671 · end of year $1,134,755

  • 15 · Other assets

    beginning of year $1,140,419 · end of year $779,430

  • 17 · Accounts payable and accrued expenses

    beginning of year $140,148 · end of year $226,506

  • 18 · Grants payable

    beginning of year $3,193,674 · end of year $7,033,207

  • 25 · Other liabilities

    beginning of year $21,070 · end of year $0

  • 27 · Net assets without donor restrictions

    beginning of year $14,379,645 · end of year $55,800,184

  • 28 · Net assets with donor restrictions

    beginning of year $15,457 · end of year $15,457

Mission and programs · 2022

Mission

ANGELMAN SYNDROME (AS) IS A NEURODEVELOPMENTAL DISORDER CHARACTERIZED BY GLOBAL DEVELOPMENT DELAYS AND SEVERE SPEECH IMPAIRMENT. A FEW INDIVIDUALS WITH AS DEVELOP FUNCTIONAL SPEECH, BUT MOST COMMUNICATE THROUGH A MIXTURE OF GESTURES, EYE GAZE, ADAPTED SIGN LANGUAGE AND AUGUMENTATIVE COMMUNICATION DEVICES. INDIVIDUALS WITH AS HAVE DEVELOPMENT DELAY AND INTELLECTUAL DISABILITIES. CURRENT RESEARCH SUGGESTS THAT NEURONAL DEVELOPMENT OCCURS CORRECTLY IN AS, BUT NEURONAL FUNCTIONING IS IMPAIRED. THIS NEURONAL IMPAIRMENT IMPACTS THE INDIVIDUAL'S ABILITY TO LEARN IN THAT SKILLS ARE ACQUIRED LESS RAPIDLY THAN IN AGE-MATCHED PEERS. THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS IS AN ORGANIZATION OF FAMILIES AND PROFESSIONALS DEDICATED TO FINDING A CURE FOR AS AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGRESSIVE RESEARCH AGENDA, EDUCATION, ADVOCACY, AND COMMUNITY SUPPORT. FAST IS COMMITTED TO ASSISTING INDIVIDUALS LIVING WITH AS TO REALIZE THEIR FULL POTENTIAL AND QUALITY OF LIFE.

Activities or mission (Part I)

THE FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) IS DEDICATED TO FINDING A CURE FOR ANGELMAN SYNDROME (AS) AND RELATED DISORDERS THROUGH THE FUNDING OF AN AGGRESSIVE RESEARCH AGENDA, EDUCATION, AWARENESS, AND ADVOCACY.

  • FAST'S PRIMARY GOAL IS TO ADVANCE RESEARCH LEADING TO A CURE FOR AS IN THE FORM OF PROVIDING GRANTS TO UNIVERSITIES TO PERFORM RESEARCH AND TESTING.

    Expenses $6,744,524 · Grants $6,744,524 · Revenue $355,507

  • AS IS A RARE DISORDER. THE COMMUNITY OF PARENTS AND CAREGIVERS OF INDIVIDUALS WITH AS RELY HEAVILY ON SOCIAL NETWORKING TO BECOME INFORMED AND SEEK ADVICE AND GUIDANCE ON THE CHALLENGES WHICH THE DISORDER PRESENTS. IT IS ONE OF FAST'S OBJECTIVES TO EDUCATE, SUPPORT, AND STRENGTHEN THIS COMMUNITY.

    Expenses $1,252,706

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • John Schuellter

    CHAIRPERSON

    Total calculated
    $0
    Hours/week
    30
  • Kelly David

    CO-VICE CHAIRPERSON

    Total calculated
    $0
    Hours/week
    30
  • Kristy Dixon

    CO-VICE CHAIRPERSON AND TREASURER

    Total calculated
    $0
    Hours/week
    25 + 2 related
  • Ben O'Connor

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5 + 2 related
  • Allyson Berent

    CHIEF SCIENCE OFFICER

    Total calculated
    $176,687
    From this org
    $0
    From related orgs
    $176,687
    Other
    $0
    Hours/week
    40 + 40 related

    Schedule J breakdown matched by us

    Base
    $0 + $135,913 related
    Bonus
    $0 + $40,774 related
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $0 + $176,687 related
  • Roy Azout

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5
  • Ryan Jacob

    DIRECTOR

    Total calculated
    $0
    Hours/week
    15 + 2 related
  • Nora Xu

    DIRECTOR

    Total calculated
    $0
    Hours/week
    5
  • Amelia Beatty

    SECRETARY

    Total calculated
    $0
    Hours/week
    30
  • Lauren Hoffer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    18
  • Megan Cross

    CHIEF INFORMATION OFFICER

    Total calculated
    $0
    Hours/week
    5
  • Kena Richert

    CFO

    Total calculated
    $188,000
    From this org
    $188,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $188,000
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $188,000
  • Alana Newhouse

    PRESIDENT/CEO

    Total calculated
    $50,000
    From this org
    $50,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    40
  • Paula Evans

    FORMER OFFICER AND DIRECTO

    Total calculated
    $176,687
    From this org
    $0
    From related orgs
    $176,687
    Other
    $0
    Hours/week
    0 + 40 related

    Schedule J breakdown matched by us

    Base
    $0 + $135,913 related
    Bonus
    $0 + $40,774 related
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $0 + $176,687 related

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Independent compensation consultant
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 3
THE BOARD OBTAINED A WRITTEN COMPENSATION ANALYSIS FROM WILLIS TOWERS WATSON, WHO SPECIALIZES IN EXECUTIVE COMPENSATION ASSESSMENTS. THE BOARD REVIEWED THIS COMPENSATION ANALYSIS, THE JOB DESCRIPTION, AND THE CURRENT NEEDS OF THE FOUNDATION TO SET THE COMPENSATION LEVELS FOR THE COO AND CFO POSITION.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

  • TEXAS A&M UNIVERSITY

    $277,778

    TRANSLATIONAL RESEARCH IN PIG MODEL OF AS

  • GENERATION AND CHARACTERIZATION OF A NEW AS MOUSE MODEL THAT RECAPITULATES THE LARGE DELETION OF HUMAN 15Q11-Q13 AND A CONTROL LINE THAT CARRIES A DELETION OF ALL GENES IN 15Q11-Q13 BUT UBE3A

  • NORTH CAROLINA STATE UNIVERSITY

    $173,873

    BANDODKAR LAB HUMAN ORGANOID ARRAYS TO STUDY AS

  • A. THE UBE3A ANTISENSE TRANSCRIPT (UBE3A-AS) IS A LONG NON-CODING MRNA THAT SILENCES EXPRESSION OF THE PATERNAL UBE3A GENE IN NEURONS. INTERRUPTION OF THIS IMPRINTING PHENOMENON CAN BE DONE THROUGH ASOS, CRISPR-GRNA OR OTHER TECHNOLOGIES LIKE MICRORNA (MIRNA). THIS PROJECT IS AIMING TO DEVELOP A STRATEGY TO SUPPRESS THE UBE3A-AS IN THE MOUSE MODEL OF AS USING MIRNAS. ADVANTAGES TO MIRNA ARE THAT THEY ARE SUBJECT TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION, WHICH CAN HELP CIRCUMVENT ISSUES RELATED TO OVEREXPRESSION OF EXOGENOUS GENETIC MATERIAL (WITH UBE3A REPLACEMENT), AND THE NEED FOR REPEATED REDOSING (WITH ASOS). MIRNA IS THOUGHT TO BE ADVANTAGEOUS OVER SHRNA DUE TO ENDOGENOUS CELLULAR PROCESSING AND REGULATION COMPARED TO OVEREXPRESSION YOU COULD GET WITH SHRNA.

Fundraising and gaming

From Schedule G of this return, as filed.

Had an agreement with a professional fundraiser (line 2a)
Not answered

Fundraising events (Part II)

Part II has at most four columns: the two largest events, the rest together, and the total.

Line Event 1 ANNUAL GALA Total
Gross receipts (line 1) $3,148,783 $3,148,783
Less contributions (line 2) $2,787,000 $2,787,000
Gross income (line 3) $361,783 $361,783
Cash prizes (line 4) — —
Noncash prizes (line 5) — —
Rent and facility costs (line 6) $759,333 $759,333
Food and beverages (line 7) — —
Entertainment (line 8) $28,000 $28,000
Other direct expenses (line 9) $180,537 $180,537
Direct expenses (line 10)
$967,870
Net income (line 11)
-$606,087

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
0
Employees, agents and contractors (line 3c)
0
Expenditures and investments (line 3c)
$0

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
UNITED KINGDOM $324,423 — $0 — —
ARGENTINE $18,000 — $0 — —
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Taxable family on this return

Schedule R Parts I, III and IV, as filed. These record ownership and control, not shared board members or money moved.

Related partnerships

Part III: related organizations taxable as a partnership, with the filer's share.

  • GENETX BIOTHERAPEUTICS LLC

    RELATED · MEDICAL RESEARCH · DE · 58.96% owned · share of income $46,248,383 · general or managing partner

  • TRANFORMATX BIOTHERAPEUTICS LLC

    RELATED · MEDICAL RESEARCH · DE · 92.63% owned · share of income -$586,331 · share of assets $494,766 · general or managing partner

Provenance

Return type
form_990
Tax year
2022
Filed
15 November 2023
IRS schema version
2022v5.0
Source object
202323199349331737

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.